Mesenchymal Stromal Cells Improve Salivary Function and Reduce Lymphocytic Infiltrates in Mice with Sjögren's-Like Disease by Khalili, Saeed et al.
Mesenchymal Stromal Cells Improve Salivary Function
and Reduce Lymphocytic Infiltrates in Mice with
Sjo ¨gren’s-Like Disease
Saeed Khalili
1, Younan Liu
1, Mara Kornete
2, Nienke Roescher
3, Shohta Kodama
4, Alan Peterson
5,
Ciriaco A. Piccirillo
2, Simon D. Tran
1*
1Faculty of Dentistry, McGill University, Montreal, Quebec, Canada, 2Department of Microbiology and Immunology, and FOCIS Centre of Excellence, Centre, Montreal,
Quebec, Canada, 3Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands, 4Department of Regenerative Medicine and Transplantation,
Faculty of Medicine, Fukuoka University, Fukuoka, Japan, 5Molecular Oncology, Faculty of Medicine, McGill University, Montreal, Quebec, Canada
Abstract
Background: Non-obese diabetic (NOD) mice develop Sjo ¨gren’s-like disease (SS-like) with loss of saliva flow and increased
lymphocytic infiltrates in salivary glands (SGs). There are recent reports using multipotent mesenchymal stromal cells (MSCs)
as a therapeutic strategy for autoimmune diseases due to their anti-inflammatory and immunomodulatory capabilities. This
paper proposed a combined immuno- and cell-based therapy consisting of: A) an injection of complete Freund’s adjuvant
(CFA) to eradicate autoreactive T lymphocytes, and B) transplantations of MSCs to reselect lymphocytes. The objective of
this was to test the effectiveness of CD45
2/TER119
2 cells (MSCs) in re-establishing salivary function and in reducing the
number of lymphocytic infiltrates (foci) in SGs. The second objective was to study if the mechanisms underlying a decrease
in inflammation (focus score) was due to CFA, MSCs, or CFA+MSCs combined.
Methodology/Principal Findings: Donor MSCs were isolated from bones of male transgenic eGFP mice. Eight week-old
female NOD mice received one of the following treatments: insulin, CFA, MSC, or CFA+MSC (combined therapy). Mice were
followed for 14 weeks post-therapy. CD45
2/TER119
2 cells demonstrated characteristics of MSCs as they were positive for
Sca-1, CD106, CD105, CD73, CD29, CD44, negative for CD45, TER119, CD11b, had high number of CFU-F, and differentiated
into osteocytes, chondrocytes and adipocytes. Both MSC and MSC+CFA groups prevented loss of saliva flow and reduced
lymphocytic infiltrations in SGs. Moreover, the influx of T and B cells decreased in all foci in MSC and MSC+CFA groups, while
the frequency of Foxp3
+ (Treg) cell was increased. MSC-therapy alone reduced inflammation (TNF-a, TGF-b), but the
combination of MSC+CFA reduced inflammation and increased the regenerative potential of SGs (FGF-2, EGF).
Conclusions/Significance: The combined use of MSC+CFA was effective in both preventing saliva secretion loss and
reducing lymphocytic influx in salivary glands.
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Introduction
Sjo ¨gren’s syndrome (SS) is a chronic autoimmune disease
characterized by infiltrates of lymphocytes in the salivary glands
[1,2]. In SS the immune system attacks the salivary glands,
particularly the acinar cells. This leads to a loss of saliva secretion
and consequently patients’ quality of life is severely compromised
due to xerostomia (dry mouth), dental caries, and oral infections
[2,3,4,5]. Unfortunately, there is no suitable treatment for SS.
Current pharmacological therapy that depends on the stimulation
of residual acinar cells frequently fails, since in many cases, all the
salivary secretory tissue has already been lost [6]. Regeneration of
destroyed salivary glands or restoration of their function would
greatly improve the quality of life for these patients.
The non-obese diabetic (NOD) mouse is a frequently used
animal model to study Sjo ¨gren’s-like disease (SS-like) as it exhibits
infiltrates of lymphocytes in the salivary glands (sialadenitis) with a
gradual loss of salivary function [1,7,8,9]. The reduced saliva
output is similar to what is observed in SS patients [8]. Our group
recently reported a two-step combined immuno- and cell-based
therapy that restored saliva flow in NOD mice with SS-like disease
[7]. The first step (immune-modifying therapy) consisted of one
injection of complete Freund’s adjuvant (CFA) to increase the
levels of endogenous tumor necrosis factor alpha (TNFa)t o
eradicate autoreactive T lymphocytes through apoptosis. The
second step (cell therapy) was injections/transplantation of major
histocompatibility complex (MHC) class I-matched bone marrow
cells from healthy mice to reselect lymphocytes [8,10,11].
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combined immuno- and cell-based therapy, no differences were
observed in focus score (number of lymphocytic infiltrates) [7]. We
concluded that CFA was insufficient to decrease the inflammatory
cell infiltrates in SGs and started to investigate for additional
approaches to our proposed combined therapy. Recent evidence
from our collaborators (DL Faustman and S Kodama) indicated
that multipotent stem cells of non-lymphoid lineage (CD45-
negative; CD45
2) from the spleen contributed to the regeneration
of bone, inner ear, cranial nerves, islets, hearts, and of particular
interest to our work, salivary glands [12,13,14,15]. The spleen and
bone marrow are closely related organs, and both are among the
first sites of hematopoiesis during gestation. However spleen cells
are not easily obtained from patients, except from trauma cases.
Bone marrow cells are clinically easier to harvest, such as from
needle aspirates, and can be expanded in large numbers. CD45
2
cells in bone marrow include the population of multipotent
mesenchymal stromal cells (MSCs). There are recent reports on
the use of MSCs, due to their anti-inflammatory and immuno-
modulatory capabilities, as a therapeutic strategy for autoimmune
diseases, such as rheumatoid arthritis, multiple sclerosis, type I
diabetes, and systemic lupus erythematosus (SLE) [16,17,18]. Our
initial study [7] used unfractionated bone marrow cells (i.e.
containing a mixture of both hematopoietic and mesenchymal
cells) and we could not conclude if the observed re-establishment
of saliva flow (therapeutic clinical effect) was due to cells from the
mesenchymal lineage or from the hematopoietic one. Therefore
the primary objective of this study was to assess the effectiveness of
an enriched fraction of CD45
2/TER119
2 cells (MSCs) in re-
establishing salivary function and in reducing the number of
lymphocytic infiltrates (foci) in salivary glands. CD45 is a trans-
membrane protein tyrosine phosphatase. It is expressed at high
levels on the cell surface of all nucleated hematopoietic cells and
their precursors [19]. The TER119 antigen is associated with
Glycophorin A on erythrocytes and is used as a marker for
erythroid cells from the early pro-erythroblast to mature
erythrocyte stages of development [20]. Non-hematopoietic
lineage is confirmed by the absence of CD45 (CD45
2) and
TER119 (TER119
2) [21]. Our second objective was to study if
the mechanism underlying a decrease in inflammation (focus
score) was due to CFA, MSCs, or a combination of CFA+MSCs.
We hypothesized that CD45
2/TER119
2 cells could be used to
develop therapies for SS patients.
Results
1- Both combined and MSCs therapies preserved normal
salivary secretion
Salivary gland function was assessed by measuring the salivary
flow rate (SFR) of 8-week old NOD mice at baseline and for 14
weeks post-therapy. SFR directly reflects function of the glands
and its decrease is the major clinical finding in patients with SS. In
untreated NOD mice, SFR continued to deteriorate during the 14
weeks follow-up period (Figure 1). SFR of CFA-treated NOD mice
(with no cell transplants) also deteriorated but to a lesser extent.
SFRs of NOD mice that received the combined immuno- and cell-
based therapy (CD45
2/TER119
2 MSCs with CFA) or the cell-
based therapy alone (CD45
2/TER119
2 MSCs) were maintained
during the 14 weeks post-therapy period and were statistically
higher than SFRs of untreated and CFA-treated NOD mice
(P,0.05; Figure 1). The composition and quality of saliva was
examined for EGF, amylase, and total protein concentrations.
These levels did not change significantly between pre-therapy (8-
week NOD mice, prior to SS-like) and post-therapy (Figure S1).
Blood glucose levels were monitored as NOD mice are known to
develop type I diabetes. Sixty percent of control NOD mice (only
receiving injections of insulin) developed diabetes at 22 weeks of
age (Figure S2; P,0.05). However, 80%–90% NOD mice in the 3
other treated groups (CFA, MSC, and MSC+CFA) showed a
relatively stable blood sugar level (normoglycemia) until 22 weeks
of age.
2- MSC therapy decreased lymphocyte infiltration and
foci formation in salivary gland
To explore the mechanism underlying the preservation of SFR
in NOD mice, salivary tissues were histologically analyzed for
inflammatory signs, gene expression levels and cell chimerism. The
focus scores (number of lymphocytic infiltrates in salivary tissue;
Figure 2) of the CFA (1.81), MSC+CFA (1.8), and MSC (1.23)
groups were all lower than the focus score of control NOD mice
(3.24; P,0.05). The size of the lymphocytic infiltrate was smaller
in NOD mice that received MSCs with or without CFA, when
compared to untreated or CFA-treated mice (Figure 2 A, B, C, D,
E). Interestingly, no lymphocytic infiltrates were detected in two
out of five NOD mice transplanted with MSCs only (Figure 2E).
3- MSC therapy lessened inflammation while combined
MSC+CFA therapy favored salivary tissue regeneration
Expression of several important growth factor/cytokine genes
involved in the pathogenesis of SS (TNF-a, TGF-b1) and in
salivary tissue regeneration/homeostasis (EGF, FGF2, IGF-IR,
AQP5) was measured (Figure 3). TNF-a mRNA were ,4 fold
lower in CFA-treated and MSC+CFA versus control NOD mice
(Figure 3 upper panel; P,0.05). NOD mice transplanted with only
MSCs had the lowest expression of TNF-a (10 fold lower than
control NOD and 5 fold lower than CFA or MSC+CFA; P,0.05).
TNF-a concentration in saliva of MSC and MSC+CFA groups
were twice lower than those of NOD controls (Figure 4 upper
panel; P,0.05). Transforming growth factor b1 (TGF-b1) mRNA
accumulated 2.5 fold lower in MSC and MSC+CFA mice versus
control NOD (Figure 3; P,0.05). Epidermal growth factor (EGF)
Figure 1. Salivary flow rates (SFRs) of NOD mice. SFRs in
MSC+CFA (black circle; n=10) and MSC (black square; n=5) groups did
not decrease during the follow-up period (22 wk of age) and were
significantly higher than SFRs of CFA-treated or control NOD groups
(n=5 per group; P,0.05). SFRs in CFA (triangular) or control (untreated;
open circle) groups continued to decrease during the follow-up period
(* P,0.05).
doi:10.1371/journal.pone.0038615.g001
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upregulated in MSC group when compared to controls (Figure 3;
P,0.05). NOD treated with the combined immuno- and cell-
based therapy (MSC+CFA) showed the highest upregulation of
EGF and FGF2 (10 and 5-fold, respectively). Insulin-like growth
factor receptor I (IGF-IR) was upregulated (4–5 fold) in the MSC
and MSC+CFA groups when compared to control NOD
(P,0.05). The water channel protein, aquaporin-5 (AQP5), was
,4 fold upregulated in treated animals (CFA alone, MSC with or
without CFA) (P,0.05). The concentration of serum EGF was 10
times higher in the MSC+CFA treated group when compared to
control NOD, and 5 times higher than the two other groups (only
CFA, or only MSC) (Figure 4 lower panel; P,0.05).
4- MSC and combined therapy decreased the
composition of T and B lymphocytes in foci, but
increased the frequency of Foxp3
+ Treg cells
Proportions of immune cells in focus score, such as T helper
(CD4
+), T cytotoxic (CD8
+), B cell (CD19
+), and BAFF, was fewer
in MSC and MSC+CFA groups when compared to control or
CFA groups (Figure 5; P,0.05). However, regulatory T cells (Treg
Foxp3
+) cells increased in MSC and MSC+CFA groups (P,0.05).
No significant difference was found for natural killer (CD49b
+) and
plasmacytoid dendritic cells (CD11c
+).
5- Transplanted CD45
2/TER119
2 cells have
characteristics of multipotent mesenchymal stromal cells
(MSCs)
Multiparameter flow cytometry was used to characterize
CD45
2/TER119
2 cells freshly isolated from the bones of eGFP
mice (before cell culture; Figure S3), and then again after three
passages in culture (before cell transplantation procedures;
Figure 6). An antibody panel to identify mouse MSCs consisting
of positive markers for Sca-1, CD106, CD105, CD73, CD29,
CD44 and negative markers for CD45, TER119 and CD11b was
used. Flow cytometry results (based on 3 experiments; mean6 SD)
of freshly isolated CD45
2/TER119
2 cells demonstrated following
frequencies; 70.75%611.52 CD45
2, 98.45%60.63 TER119
2,
97.50%60.56 CD11b
2 and 46.85%63.04 Sca1
+, 62.75%62.75
CD106
+, 55.0%63.67 CD105
+, 47.7%60.56 CD73
+,
87.7%62.82 CD29
+, 40.9%64.52 CD44
+ (Figure S3). After
three passages in culture, these adherent CD45
2/TER119
2 cells
were enriched to 96.1%65.09 CD45
2, 97.93%62.80 TER119
2,
99.00%60.84 CD11b
2, and 83.45%61.34 Sca1
+,
73.72%613.34 CD106
+, 60.44%69.91 CD105
+, 23.92%66.55
CD73
+, 87.85%62.05 CD29
+, 84.45%64.59 CD44
+ (Figure 6).
The number, size and frequency of colony-forming unit fibroblasts
(CFU-F) were statistically higher in CD45
2/TER119
2 cells than
unfractionated bone marrow cells (Figure 7; P,0.05). CD45
2/
TER119
2 cells underwent osteogenic, chodrocytic and adipocytic
differentiation when cultured in differentiating media (Figure 7).
All these characteristics indicated that transplanted CD45
2/
TER119
2 cells were multipotent mesenchymal stromal cells
(MSCs).
6- Transplanted male-eGFP MSC donor cells did not
engraft in salivary tissues of female NOD mice
Fluorescence in situ hybridization (FISH) and immunostaining
were used to detect the male (Y-chromosome) and eGFP markers
of transplanted MSCs in female NOD salivary tissues, respectively.
No Y-chromosome or eGFP-positive cells were detected (Figure 8).
Salivary tissues also were investigated by PCR for the presence of
Figure 2. Infiltrate of lymphocytes in salivary glands of NOD mice. A–E: H&E staining showing size of the lymphocytic infiltrations
(delineated with a yellow line and arrows) in NOD that were untreated (A), CFA-treated (B), MSC+CFA (C), MSC cells (D). In 2 of the 5 NOD mice
transplanted with MSC only, no lymphocytic infiltrates were noted (E). Scale bar: 140 um for all images. F: Graph showing distribution of focus score
(n=5 to 9 mice per group). The mean focus score was significantly higher in control (3.24) versus CFA (1.81), MSC (1.23), and MSC+CFA (1.8) NOD
groups (* P=0.02).
doi:10.1371/journal.pone.0038615.g002
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(Figure 8).
Discussion
The major findings of this study were as follows
1. Both MSC and MSC+CFA groups prevented loss of saliva flow
and reduced lymphocytic infiltrations in salivary glands during
the 14 weeks post-therapy period.
2. MSC therapy reduced inflammation (TNF-a, TGF-b, focus
score).
3. Combined therapy (MSC+CFA) reduced inflammation and
increased the regenerative potential of salivary glands (EGF,
FGF2, IGF-IR).
4. Both MSC and combined therapy decreased the number of T
and B cells in foci, while increasing regulatory T cells (Treg).
5. CD45
2/TER119
2 cells demonstrated characteristics of mul-
tipotent mesenchymal stromal cells (MSCs) as they were
positive for markers Sca-1, CD106, CD105, CD73, CD29,
CD44, negative for CD45, TER119, CD11b, had high number
of CFU-F, and differentiated into osteocytes, chondrocytes and
adipocytes.
6. A lack of male eGFP MSCs engrafted in the salivary
parenchyma of transplanted female NOD mice suggested that
tissue repair/regeneration originated from endogenous salivary
cells.
Salivary secretion function was measured using salivary flow
rate (SFR) pre- and post-cell transplantation. As expected, SFR of
control NOD mice deteriorated during the follow-up period [22].
MSC-treated groups (with or without CFA) maintained their SFRs
(Figure 1). SFR of CFA-treated mice also deteriorated, but to a
lesser extent when compared to control NOD. There was no
statistically significant difference in SFR between MSC-treated
Figure 3. Relative gene expression of key inflammatory cytokines and growth factors involved in the pathogenesis of Sjo ¨gren’s
syndrome. TNF-a and TGF-b mRNAs were downregulated in CFA-treated and MSC+CFA versus control NOD mice (upper panel; * P,0.05). NOD mice
transplanted with only MSCs had the lowest expression of TNF-a (* P,0.05). EGF, IGF-IR and FGF-2 mRNAs (middle and lower panels) were
upregulated (* P,0.05) in MSC and MSC+CFA groups. The combined therapy (MSC+CFA) had the highest upregulation for regenerative genes (EGF,
FGF-2). n=4 to 8 mice per group.
doi:10.1371/journal.pone.0038615.g003
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age (Figure 1). We have observed, in this study and in our previous
one [7], that CFA was helpful in restoring SFR for a relatively
short-term but as the follow-up time was longer, this effect was lost.
This may be due to the limited action/stimulus of CFA on salivary
glands, as explained below.
Normally, autoreactive T cells are destroyed in the bone
marrow or thymus during the process of negative selection. In
autoimmune diseases, autoreactive T cells survive after having
evaded negative selection. In the NOD mouse model, autoreactive
T cells escape negative selection because of a proteasomal defect
that alters protein processing, including processing of self-antigens
for display on their cell surface. Without appropriate display of
self-antigens, autoreactive T cells avoid being seen as ‘self’, and
thus avoid targeted death. Their survival leads to onset or
deteriorating of autoimmunity. But the underlying proteasomal
defect in these cells also renders them exquisitely sensitive to
TNFa-induced apoptosis. Because of the dysfunctional protea-
some, autoreactive T cells of the activated type, do not form NF-
kB. Lacking functional NF-kB in autoreactive T cells, they remain
sensitive to TNFa-induced apoptosis. TNFa-induced apoptosis
sensitivity can be exploited for therapeutic purposes. Several
studies in the NOD mouse find that agents which induce TNF-a,
such as bacillus Calmette-Gue ´rin (BCG) or complete Freund’s
adjuvant (CFA, as in our study), have a similar effect to direct
administration of TNF-a [10]. We and others have proposed a
therapy using TNF-a (or TNFa-inducers such as CFA or BCG) to
selectively kill autoreactive T cells in type I diabetes and SS [7,23].
Treatment with TNF-a appears to offer a highly targeted strategy
to destroy autoreactive activated T cells and interrupt the
pathogenesis of autoimmunity [10,24]. TNF-a does not appear
to harm normal T cells or other tissues, presumably due to their
active form of NF-kB. Our findings showed some (short-term)
benefits of CFA for SS, but also that one single injection of CFA
(to induce TNF-a) was insufficient to completely restore salivary
function. TNF-a does not eliminate the autoreactive naı ¨ve T cells,
which will become pathogenic on exposure to self-antigens. To
prevent eventual self-tissue recognition and activation, autoreac-
Figure 4. Measurements of TNFa and EGF concentrations in saliva and serum. Upper panel (A), as expected, the level of TNFa in saliva was
significantly higher (*P,0.05) in non-treated NOD mice at week 22 (established Sjo ¨gren’s-like disease) when compared to week 8 (before disease
onset). At the end of the experimentation period (week 22), treated MSC and MSC+CFA mice had two times less TNFa levels than non-treated NOD
(*P,0.05). Lower panel (B), concentrations of serum EGF was significantly higher in MSC+CFA group versus control, CFA, and MSC groups (n=4 to 8
mice per group; P,0.05).
doi:10.1371/journal.pone.0038615.g004
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such as by introducing MHC class I-matched cells (such as spleen,
bone marrow, or MSCs) that could also be used to induce tissue
repair/regeneration.
CD45
2/TER119
2 cells used in this study were tested for their
stem cell properties. The ‘‘three minimum criteria’’ used to
characterize MSCs are: a) plastic-adherent, b) specific surface
antigen expression, and c) in vitro differentiation potential into
osteocytes, chondrocytes and adipocytes [25]. Adherent CD45
2/
TER119
2 cells were grown in MSC culture media for 3 passages.
Despite the lack of a specific surface marker to identify MSC, the
use of a panel of surface markers with flow cytometry is an
accepted practice to characterize both primary and cultured
MSCs. The positive markers for mouse MSCs are vascular cell
adhesion molecule 1 (CD106), endoglin (CD105), 59-nucleotidase
(CD73), integrin beta-1 (CD29), hyaluronidase acid receptor
(CD44), and stem cell antigen-1 (Sca-1) [26,27]. These positive cell
surface markers, together with the absence of hematopoietic
markers such as Ter119, CD45, and CD11b can be used to
characterize mouse MSCs [27]. CD45
2/TER119
2 cells used here
were between 96–99% CD45, TER119 and CD11b negative
(Figure 6). They were high (73–88%) for Sca1, CD106, CD29,
CD44, moderate (60%) for CD105, and low (24%) for CD73.
However, transplanted cells did not engraft or differentiate into
salivary epithelial cells, as demonstrated by absence of male and
eGFP cells in female NOD salivary glands (Figure 8). Recent
studies reported functional improvements in several animal models
and in certain patients occurred with transient appearances of the
transplanted cells. This finding led to a new paradigm that
transplanted cells delivered their therapeutic function, such as
repairing tissue and influencing the immune response, through
paracrine secretions and cell-cell interactions [16,28]. MSCs were
Figure 5. Immunohistochemical staining of salivary glands at week 22 (n=3 to 5 mice per group). Cells positive for Foxp3
+ (regulatory T
cells), CD8
+ (T cytotoxic), CD4
+ (T helper), BAFF and CD19
+ (B cells) appeared brown in the foci. Graphs on the right represent percentage of positive
cells occupying the area of the focus score. Regulatory T cells (Foxp3
+) increased in MSC and MSC+CFA groups (P,0.05) while T cytotoxic (CD8
+), T
helper (CD4
+), BAFF, and B cell (CD19
+) decreased after MSC or MSC+CFA treatment, when compared to control and CFA groups (* P,0.05).
doi:10.1371/journal.pone.0038615.g005
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immune system [14,15,29,30]. In autoimmune diseases, MSCs
inhibited proliferation of T cytotoxic, natural killer and B cells,
cytokine production, and differentiation of monocytes into
antigen-presenting dendritic cells [17].
This study found that the proportion of immune cells in salivary
glands was reduced in NOD treated with MSC (either with or
without CFA; Figure 5). The numbers of T helper, T cytotoxic,
and B cells were significantly decreased when compared to the
CFA or control groups. The B-cell-activating factor (BAFF)
promotes B-cell survival and allows autoreactive B cells to escape
from apoptosis and to produce pathogenic autoantibodies [31]. A
decrease in their numbers was observed in MSC and MSC+CFA
treated groups. As Treg cells expressed the critical fork head box p3
(Foxp3) transcription factor to maintain immune self-tolerance by
actively suppressing self-reactive lymphocytes, we postulated that
Foxp3
+ Treg cells inhibited the inflammation and disease [32,33].
Consistently, recent studies suggest that treatment with MSCs
augment Foxp3
+ Treg numbers in autoimmune rheumatic disease
[34]. Interestingly, the frequency of Foxp3
+ Treg cells increased in
MSC and MSC+CFA groups and correlated with the reduced
inflammation observed in these groups.
Elevated production of inflammatory cytokines, such as TNF-a,
is a common finding in the pathogenesis of SS [1,2,35,36,37,38].
TGF-b is involved in salivary gland development and homeostasis;
its production is increased in inflammatory and abnormal
conditions [35]. MSC and MSC+CFA treated groups showed a
down regulation of both TNF-a and TGF-b genes (Figure 3). The
CFA group also showed a comparable down regulation of TNF-a
as the MSC-treated groups and this may be due to its different
mechanism of action (see explanation on CFA, above). Our results
showed that the MSC-therapy alone was effective in reducing
inflammation (TNF-a, TGF-b, focus score). However when it was
combined with CFA, there was an added benefit for tissue repair/
regeneration (FGF-2, EGF). FGF-2 is a modulator of cell
proliferation, differentiation, angiogenesis, and wound healing
[39]. FGF-2 increased re-epithelialization in salivary glands [40]
and healing of oral mucosa ulcers [41]. EGF is a growth factor
secreted by salivary ductal cells and is involved in the growth,
regeneration, and maintenance of salivary glands. In addition,
EGF has an anti-apoptotic function in salivary epithelial cells [42].
High levels of EGF were measured in the serum of MSC+CFA
mice (Figure 4, lower panel). Salivary glands are known mainly as
an exocrine gland. However, they also act (less well-known) as an
endocrine gland and can secrete proteins/molecules into the blood
stream [43]. The higher levels of serum EGF and its mRNA in
MSC+CFA mice suggest that the preservation of salivary secretory
function was a result of endogenous tissue regeneration/repair.
This paper focuses mainly on the therapeutic effects of
MSC+CFA within the salivary glands of SS-like NOD mice.
However since this is a systemic therapy likely to exert
immunomodulatory functions, future studies investigating lym-
phocytes activation/differentiation in lymphoid tissues (such as
cervical lymph nodes and the spleen) are desired to shed more light
on the possible mechanisms of our combined therapy. Also
measuring serum levels of autoantibodies and cytokines involved
in Sjo ¨gren’s syndrome would be useful.
Materials and Methods
Animals
All procedures with animals were carried out under protocols
approved by the Facility Animal Care Committee of McGill
University.
Recipients. 8-week old female NOD mice with Sjo ¨gren’s-like
disease (SS-like) from Taconic Farms (Germantown, NY) were
randomized into four groups and treated with: a) MSC plus CFA
(MSC+CFA group; n=10), b) MSC without CFA (MSC; n=5), c)
CFA injection only (CFA group; n=5), or d) no cell injection, no
CFA, but daily injections of insulin to control the blood sugar
levels (Control untreated group; n=5). Female NOD mice
belonging to the CFA and MSC+CFA groups received one
Figure 6. Flow cytometry analysis of CD45
2/Ter119
2 cells. After 3 passages, CD45
2/Ter119
2 cells were stained with the following surface
markers: CD45, Ter119, CD11B, Sca-1, CD106, CD105, CD73, CD29 and CD44. Data are representative of at least three separate experiments. This
experiment shows 97.8% CD45
2, 99.7% TER119
2, 99.6% CD11b
2 and 84.4% Sca1
+, 86.5% CD106
+, 64.1% CD105
+, 19.3% CD73
+, 86.4% CD29
+, 81.2%
CD44
+ cells.
doi:10.1371/journal.pone.0038615.g006
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NOD mice from MSC+CFA and MSC groups were transplanted
with male eGFP MSCs bi-weekly for 2 weeks. The use of male
eGFP donor cells allowed for the localization of Y-chromosome
and eGFP cells in female NOD mice salivary tissue.
Donors (CByB6F1-eGFP male) mice: male GFP transgenic mouse
[C57BL/6-TgH (ACTbEGFP)10sb/J] (stock number # 003291)
were bred with female BALB/c mice (stock number # 00651)
from Jackson Laboratory, NY. The transgenic mouse line has an
‘‘enhanced’’ GFP (eGFP) cDNA under the control of a chicken
beta-actin promoter and cytomegalovirus enhancer makes all of
the tissues, with the exception of erythrocytes and hair, appear
green under excitation light (488 nm light source). To screen the
newborns for the expression of eGFP, they were: A) illuminated
with a UV light (UVP, UK cat no # 1199069) and B) genotyped
by PCR. DNA was extracted (PureLink Genomic DNA mini kit,
Invitrogen, USA, Cat no# K1820-02) from a tail biopsy and
analyzed by PCR for the presence of the eGFP gene. The primers
were (forward) 59-GCA-CCA-TCT-TCT-TCA-AGG-ACG-AC-
39 and (reverse) 59-CGT-GGT-AGA-AGA-AGT-TCC-TGC-TG-
39. PCR amplification was done as follows: 94uC for 7 minutes,
94uC for 1 minute, 59.6uC for 1 minute, and 72uC for 1.30 min-
ute for 29 cycles; and 72uC for 10 minutes.
Cells
Isolation and enrichment of CD45
2/TER119
2 cells from
bone marrow and compact bone. eGFP transgenic donor
mice were sacrificed. Muscles were removed to expose the femur
and tibia. These bones were crushed according to the manufac-
turer’s instruction (Cat No# 19771, Stem cells Technologies,
Vancouver, BC). Unwanted hematopoietic (non-mesenchymal)
cells were removed with antibodies directed against CD45 and
TER119. These hematopoietic cells were bound to magnetic
particles, separated using a magnet, and discarded. This strategy
allowed for the negative selection of mesenchymal cells, which
were CD45
2/TER119
2, from the compact bone and its marrow.
The isolated cells were plated in 100 mm cell culture dish using
MesenCult MSC basal medium and stimulatory supplements (Cat
No#05511, Stem cells Technologies). These adherent cells were
cultured for 3 passages (3 weeks).
Cell transplantation. 1610
7 CD45
2/TER119
2 cells were
injected into female NOD recipients through the tail vein, twice a
week for two consecutive weeks. No cells were injected into NOD
Figure 7. Functional assays for multipotent mesenchymal stromal cell (MSCs). Photomicrographs of CD45
2/TER119
2 cells that undergone
chondrocytic, osteogenic and adipocytic differentiation when cultured in differentiation media. Lower right photomicrograph represents CD45
2/
TER119
2 cells cultured in non-differentiating media (negative control). Collagen II (red) and DAPI (blue nuclei) are used to identify chondrocytes. Von
kossa (black) and oil red stainings were used to identify osteoblasts and adipocytes, respectively. Graphs represent the number, size, and frequencyo f
colony-forming unit fibroblasts (CFU-F) of CD45
2/TER119
2 cells versus whole bone marrow cells. All three graphs show that CD45
2/TER119
2 cells
had higher CFU-F than whole bone marrow cells (* P,0.05).
doi:10.1371/journal.pone.0038615.g007
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freshly mixed with an equal volume of physiological saline and
injected (50 ml) into each hind footpad simultaneously with the first
CD45
2/TER119
2 cells injection. CFA was also injected once in
NOD mice of the CFA group. No CFA was injected in mice of the
control group [7,8].
Flow cytometry. Staining for surface phenotyping were done
with the following fluorochrome-conjugated mAbs: anti-Ter119
(TER-119), anti-CD11b (M1/70), anti-CD106 (VCAM-1)(429),
anti-CD105 (MJ7/18), anti- Ly-6A/E (Sca-1) (D7), anti-CD73
(TY/11.8), anti-CD29 (eBioHMb1-1), anti-CD44 (IM7)
(eBioscience, San Diego, CA), anti-CD45 (30-F11), (BD Biosci-
ence, Mississauga, Ontario). Data were acquired on a BD
LSRFortessa (BD) and analyzed with Flowjo software (Tree Star).
Flow cytometry experiments were repeated 3 times.
Functional assays for multipotent mesenchymal stromal
cell (MSC). The number, size, and frequency of Colony
Forming Unit- Fibroblast (CFU-F) between cultured CD45
2/
TER119
2 and bone marrow cells for 10–13 days were assessed
using the CFU-F kit (Cat No # 28374, Stem cell technologies, BC.
Canada). A colony forming unit is defined as .40 cells. CD45
2/
TER119
2 cells were differentiated into osteocytes, adipocytes and
chondrocytes (‘differentiation assay’) using stimulatory supple-
ments (Cat No # 05503, Stem Cell Technologies, or # CCM006,
R&D Systems, MN) according to the manufacturer’s instructions.
Von Kossa and oil red histochemical stainings were used to detect
osteocytes and adipocytes, respectively. Immunofluorescence
staining to collagen II was used to identify chondrocytes (Collagen
II antibody, # AF3615; Northern Lights 557-conjugated anti-
sheep IgG, # NL010, R&D Systems, MN). All experiments were
done in duplicate and repeated 3 times.
Figure 8. Absence of eGFP and male MSC (CD45
2/TER119
2) donor cells in salivary tissues of female NOD mice. Top panel: eGFP
detection of MSC donor cells by immunostaining. (A) Salivary tissues from the eGFP donor mouse (positive control) versus (B) the non-eGFP mouse
(negative control). (C) NOD mice transplanted with MSCs were negative for eGFP cells. Middle panel: Y-chromosome detection of male MSCs by FISH.
(D) male and (E) female salivary tissues used as positive and negative controls, respectively. (F) Female NOD mice transplanted with male MSCs
showed no Y-chromosome signal in their salivary glands. Bottom panel: (G) CByB6F1-eGFP transgenic mouse (arrow) and (H) the isolated donor eGFP
MSCs before transplantation. Cell nuclei are stained in blue (Hoechst 33258). (I) PCR amplification did not detect the Y-chromosome and eGFP signal
in salivary glands of MSCs transplanted NOD mice (n=11).
doi:10.1371/journal.pone.0038615.g008
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Secretory function of the salivary glands (salivary flow
rate; SFR). SFR was obtained by inducing mild gas anesthesia
to NOD mice with 5% Isoflurane, 5% Halothane, and 0.5–1 L/
min oxygen (as per animal facility protocols at McGill University).
Whole saliva was collected after stimulation of secretion using
0.5 mg pilocarpine/kg body weight administered subcutaneously.
Saliva was obtained from the oral cavity by micropipette, placed
into pre-weighed 0.5-ml microcentrifuge tubes. Saliva was
collected for a 10-minute period and its volume determined
gravimetrically. SFR was determined at week 8 (baseline), week
18, and week 22 of age [7].
Analysis of saliva quality/composition. The concentra-
tion of proteins in saliva was measured by the bicinchoninic acid
assay method (BCA; Thermo Fisher Scientific Cat no # 23225).
Levels of epidermal growth factor (EGF) were measured by ELISA
(R&D Systems, Minneapolis, MN, Cat no # MGE00). Amylase
activity was measured with a colorimetric method (Salimetrics,
State College, PA, Cat no # 1-1902). All measurements were
performed at the beginning (baseline; week 8) and at the end of the
study (week 22 of age).
Salivary tissue and serum analysis
1- Fluorescence in situ hybridization (FISH). Was done,
as previously described [7], to detect male transplanted cells in
female NOD mice.
2- PCR. was also used to detect male transplanted cells in
female NOD mice. DNA was extracted from submandibular
glands and purified (PureLink Genomic DNA Mini kit, cat
K1820-02, Invitrogen). The sequences for the Y-chromosome
sense primer were 59 AAT-TGA-CAG-CAT-CTA-CGT-ACT-
GGA-GC 39, and antisense primer, 59 TCC-AGG-AGC-TGA-
TAA-GCA-TAG-AGA-GC 39, and PCR was performed accord-
ing to the Platinum Supermix protocol (Invitrogen).
3- Immunostaining. was done to detect eGFP. Salivary
sections were stained overnight with a rabbit polyclonal antibody
to mouse GFP (1:100dilution; Aabcam # ab290), one hour with
Rhodamine red–conjugated rabbit secondary antibody (Jackson
ImmunoResearch), and then stained with DAPI.
4- Focus score. As previously described [7], half of a
submandibular gland per mouse was fixed in 10% formalin and
embedded in paraffin. Sections were cut at 5–8 mm thick and
subsequently stained with hematoxylin and eosin (H&E). A score
of 1 is a foci (aggregate) of at least 50 inflammatory cells per
4m m
2 of salivary tissue.
5- Immunohistochemistry. (IHC): Salivary sections were
blocked for endogenous peroxidase (Dako # S2003) and
incubated with normal rabbit serum (Dako # X0902). They were
then stained with primary antibodies (CD4 # 550278, CD8 #
550281, CD19 # 550284, and CD49 # 559987, BD Pharmin-
gen), CD11c (Abcam # ab33483), BAFF (Enzo-lifescience #
ALX-804-131-400), and FoxP3 (eBioscience #14-5773-80, Clone
FJK-16s) for 2 hours at room temperature. Polyclonal rabbit anti-
Rat antibody biotinynlated, as secondary antibody, was applied for
1 hour. Visualization was done using the DAB system (Dako #
K3468). Finally, sections were counterstained with hematoxylin
(Fisher # BP2424-25 and methyl green (Dako # 1962).
Quantification of IHC result: The surface area occupied by target
cells was assessed under 6400 magnification by light microscopy
for 3 tissue sections per gland. All focus scores per section were
analyzed by NIH J Image software (NIH).
6- Quantitative Real-Time PCR (qRT-PCR). Gene
expression analyses were performed using an Applied BioSystems
quantitative Real Time PCR (qRT-PCR) system (model 7500).
Total RNA was extracted from the submandibular glands with
TRIZOL reagent (Invitrogen, Carlsbad, CA). The first-strand
cDNA synthesis was performed by using Thermoscript RT-PCR
system (Invitrogen, cat no # 11146-016) and qRT-PCR was done
using 1 mg RNA per sample and TaqMan Universal Master Mix
(Applied Biosystems). The probes and primers sequences were:
Tumor necrosis factor alpha (TNF-a; Assay ID: Mm00443258),
Epidermal Growth Factor (EGF; assay ID: Mm 00438696),
Transforming Growth Factor-b (TGF-b; assay ID: Mm01178820),
Aquaporin 5 (AQP5; Assay ID: Mm 437578), insulin like growth
factor receptor 1 (IGF-IR; Assay ID: Mm00802841), (FGF-2;
Assay ID: Mm00433287) and glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH Assay ID: Mm99999915-g1), used as an
endogenous reference running at 50uC for 2 min, 95uC for
10 min, and 40 cycles [95uC for 15 s, 60uC for 1 min]).
7- Serum Preparation. blood was drawn by cardiac
puncture and held in a vertical tube for 15 minutes until it
clotted. It was then centrifuged at 3000 RPM for 10 minutes and
the serum removed.
Statistical Analysis
To determine statistical significant differences (P,0.05), Linear
Mixed Models and ANOVA analysis (Tukey’s Post-Hoc test) were
used. Subjects (data from mice) between and within the groups
were compared at different time points using SPSS version 17
(IBM, USA).
Supporting Information
Figure S1 Saliva composition. Total protein concentrations
(A), EGF (B), and amylase activity (C) were not significantly
different among the groups at week 8 (baseline) versus week 22
(end of experiment) (P.0.05). (n=5 to 9 mice per group)
(TIF)
Figure S2 Kaplan–Meier plot for normoglycemia. Blood
sugar levels in control (square), CFA (triangle), MSC (diamond)
and MSC+CFA (circle) treated NOD mice were monitored for 22
weeks. All mice were normoglycemic from the start of the
experiment (8 weeks) until 12 weeks of age. The first diabetic
mouse was diagnosed in the control group (square) at week 13, and
60% of control mice developed diabetes at week 21 of age (*
P,0.05). However, ninety percent of mice in MSC and
MSC+CFA groups (circle and diamond) and eighty percent of
mice in the CFA group were normoglycemic during the course of
the experiment.
(TIF)
Figure S3 Flow cytometry analysis of freshly isolated
CD45
2/Ter119
2 cells (before being placed in culture).
Cells were stained for the following surface markers: CD45,
Ter119, CD11B, Sca-1, CD106, CD105, CD73, CD29 and
CD44. Data are representative of at least three separate
experiments. This experiment shows 78.9% CD45
2, 98%
TER119
2, 97.1% CD11b
2 and 49.5% Sca1
+, 60.8% CD106
+,
57.6% CD105
+, 47.3% CD73
+, 89.7% CD29
+, 37.7% CD44
+.
(TIF)
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